

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

**CHANGE OF JOINT COMPANY SECRETARY AND PROCESS AGENT
AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17
OF THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Directors**”) of Alphamab Oncology (the “**Company**”), hereby announces that Ms. WONG Yee Man (“**Ms. WONG**”) tendered her resignation as a joint company secretary (the “**Joint Company Secretary**”) and ceased to serve as an agent for the service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) under the Rule 19.05(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) of the Company with effect from July 20, 2020.

Ms. WONG has confirmed that she does not have any disagreement with the Board and there are no other matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Following the resignation of Ms. WONG, the Board is pleased to announce that Ms. CHAN Lok Yee (“**Ms. CHAN**”) has been appointed as a Joint Company Secretary and the Process Agent of the Company with effect from July 20, 2020.

Ms. CHAN is currently a manager of Corporate Services of Vistra Corporate Services (HK) Limited. She has over six years of experience in providing a full range of company secretarial and compliance services and is currently serving a portfolio of clients including public listed companies and private companies. Ms. CHAN has been an associate member of The Hong Kong Institute of Chartered Secretaries and an associate member of The Institute of Chartered Secretaries and Administrators in United Kingdom since 2015.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the acting by Mr. SHUAI Qi Terry (“**Mr. SHUAI**”) as a Joint Company Secretary for a three-year period from the date of the Company’s shares listed on the Main Board of the Stock Exchange (i.e. December 12, 2019) (the “**Waiver Period**”), on the condition that Mr. SHUAI would be assisted by Ms. WONG, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period, and the Waiver would be revoked if Ms. WONG ceases to provide assistance to Mr. SHUAI. The Waiver was revoked upon Ms. WONG’s resignation on July 20, 2020.

The Company has applied to the Stock Exchange and has been granted with a new waiver (the “**New Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (i.e. from July 20, 2020 to December 11, 2022) (the “**New Waiver Period**”) in relation to the eligibility of Mr. SHUAI to act as a Joint Company Secretary, on the condition that:–

- (i) Mr. SHUAI will be assisted by Ms. CHAN during the New Waiver Period;
- (ii) the Company shall notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that after the end of the New Waiver Period, the Company will be able to demonstrate that Mr. SHUAI satisfies the Rules 3.28 and 8.17 of the Listing Rules, having had the benefit of Ms. CHAN’s assistance such that a further waiver will not be necessary; and
- (iii) the Company will announce the details of the New Waiver, including its reasons and conditions.

The New Waiver applies to this case only and will be revoked immediately if and when Ms. CHAN ceases to provide assistance to Mr SHUAI. The Stock Exchange may withdraw or change the New Waiver if the Company’s situation changes.

The Board would like to take this opportunity to express its gratitude to Ms. WONG for her valuable contributions to the Company during her tenure of service and extend its warm welcome to Ms. CHAN on her new appointment.

By order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, July 20, 2020

As of the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.